Last reviewed · How we verify

NCT05025111

Entia Liberty: Capillary Validation

Completed Last updated 27 January 2023
What this trial tests

trial testing Entia Liberty in Cancer in 150 participants. Completed in 26 October 2022.

Timeline
12 September 2022
Primary endpoint
26 October 2022
26 October 2022

Quick facts

Lead sponsorEntia Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date12 September 2022
Primary completion26 October 2022
Estimated completion26 October 2022
Sites2 locations across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Entia Ltd

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a clinical performance validation study to evaluate the performance of the Entia Liberty device. Patients undergoing routine venepuncture blood tests will be recruited to have an Entia Liberty test (by finger-prick) done on them by a trained healthcare professional. The results from that finger-prick test will be compared against the results from the routine venepuncture blood test (reference method) and subsequently, excess blood from the routine venepuncture test will be run on another Entia Liberty device in the laboratory. All three results (Entia Liberty capillary, Entia Liberty venous and gold standard venous) will be compared against each other to prove Entia Liberty's performance claims.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Entia Liberty

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Entia Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05025111.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing